IC
CATX icon

Ikarian Capital’s Perspective Therapeutics CATX Stock Holding History

Ikarian Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-107,200
Closed -$342K – 179
2024
Q4 		$342K Buy
107,200
+30,100
+39% +$246K 0.05% 139
2024
Q3 		$1.03M Buy
+77,100
New +$1.03M 0.14% 97

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ikarian Capital's CATX Position: Q1 2025 in Review

Ikarian Capital sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 108,300 shares — an estimated $345K sold.

Ikarian Capital first reported a position in CATX in Q4 2024 and held it in 1 quarter. The position peaked at $345K in Q4 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Ikarian Capital reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 108,300 Perspective Therapeutics shares in Q1 2025, an estimated $345K.
  • Ikarian Capital first reported a position in Perspective Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ikarian Capital's Perspective Therapeutics position peaked at $345K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.